EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright

EyePoint Pharmaceuticals received a second consecutive positive recommendation from an independent DSMC to continue its Phase 3 DURAVYU (vorolanib intravitreal insert) LUGANO and LUCIA trials without protocol changes, prompting H.C. Wainwright to reiterate a Buy and $23 price target (about 61% upside from the $14.28 share price) as the company completes enrollment and the U.S. LUGANO trial targets topline data in mid-2026; shares have jumped 24% in the past week and roughly 130% over six months. However, the company reported a weak Q3 2025 (EPS -$0.85 vs -$0.77 expected; revenue $0.966m vs $3.46m expected) and filed a prospectus supplement for up to $200m of common stock under its Form S-3 via a Controlled Equity Offering with Cantor Fitzgerald, highlighting near-term funding/dilution risk despite reduced clinical-safety risk and a clear mid-2026 catalyst.

Analysis

An independent Data Safety Monitoring Committee issued a second consecutive positive recommendation to continue both Phase 3 DURAVYU trials (LUGANO and LUCIA) without protocol modifications, with both trials fully enrolled (432 patients in U.S. LUGANO; over 400 in LUCIA) and all patients having reached the Week 8 visit while ~25% reached their second planned dose at Week 32. EyePoint confirmed the LUGANO trial remains on track to report topline data in mid-2026, reducing near-term clinical-safety risk and preserving a clear binary catalyst for valuation updates. H.C. Wainwright reiterated a Buy and $23 price target (about 61% above the $14.28 share price), while analyst targets range $20–$68; the stock has rallied ~24% in the past week and ~130% over six months, indicating strong investor positioning around the clinical news. Offsetting positives, Q3 2025 results missed expectations (EPS -$0.85 vs. -$0.77; revenue $0.966m vs. $3.46m expected) and the company filed a prospectus supplement to sell up to $200m of common stock under a controlled equity offering with Cantor Fitzgerald, creating near-term funding and dilution risk that materially affects payoff to equity holders.

Key Decisions for Investors

• Consider selective accumulation on meaningful pullbacks to reflect the favorable DSMC safety readthrough and a mid-2026 topline catalyst, but size exposure as a binary clinical outcome dominates valuation
• Treat the announced $200m equity shelf and recent Q3 miss as a dilution/funding risk—avoid adding materially to positions until the offering terms and timing are clarified
• Monitor trial operational readouts (second-dose uptake, any further DSMC statements) and the LUGANO topline in mid-2026 as primary value inflection points, consider using options to express exposure with defined downside
• If holding material long exposure, consider protective hedges (puts or collars) ahead of financing announcements and the mid-2026 data release to manage volatility and potential dilution impact